Amneal (NYSE: AMRX) Co-CEO receives major performance-based RSU award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Patel Chintu reported acquisition or exercise transactions in this Form 4 filing.

Amneal Pharmaceuticals reported that Co-CEO Chintu Patel received a grant of 544,663 performance-based restricted stock units, each tied to one share of Class A common stock. The award vests based on the stock achieving specified average closing price targets over a three-year performance period.

The number of shares ultimately earned can range from 0% to 200% of the target amount, depending on performance. Any earned units are scheduled to vest in full on February 28, 2029. This is a compensation grant at no cash cost per unit, not an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Patel Chintu

Role Co-CEO

Type	Security	Shares	Price	Value
Grant/Award	Performance-Based Restricted Stock Units	544,663	$0.00	--

Holdings After Transaction: Performance-Based Restricted Stock Units — 544,663 shares (Direct)

Footnotes (1)

Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Form 4 Insider Transactions: What Each Field Means →

03/27/2026 - 04:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Chintu

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER

NEW JERSEY

08807

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Co-CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance-Based Restricted Stock Units	⁽¹⁾	03/02/2026		A		544,663		⁽²⁾	⁽²⁾	Class A Common Stock	544,663	$0	544,663	D

Explanation of Responses:

1. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Remarks:

This amended Form 4 amends and restates the Form 4 filed on March 3, 2026 (the "Original Form 4") and is being filed to correct the number of restricted stock units and performance-based restricted stock units granted to the reporting person. The Original Form 4 inadvertently reported a grant of restricted stock units; however, 100% of the grant was of performance-based restricted stock units.

	/s/ Denis Butkovic, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Amneal (AMRX) disclose for Co-CEO Chintu Patel?

Amneal disclosed that Co-CEO Chintu Patel received a grant of 544,663 performance-based restricted stock units. Each unit represents a contingent right to one share of Class A common stock, with vesting based on future stock price performance over a defined three-year period.

How many performance-based RSUs did Amneal (AMRX) grant to Co-CEO Chintu Patel?

The company granted Chintu Patel 544,663 performance-based restricted stock units. These units are a form of equity compensation rather than a cash transaction, and the actual shares earned will depend on Amneal’s Class A common stock price performance over the three-year performance period.

When do Chintu Patel’s Amneal (AMRX) performance-based RSUs vest?

Any performance-based restricted stock units earned by Chintu Patel are scheduled to vest in full on February 28, 2029. That date marks the end of the three-year performance period used to measure Amneal’s average closing stock price against preset targets for the award.

What performance conditions apply to Amneal (AMRX) Co-CEO Chintu Patel’s RSU award?

The RSUs vest based on Amneal’s Class A common stock achieving specified average closing price targets at the end of the three-year performance period. Depending on results, the shares actually earned can range from 0% to 200% of the 544,663 target performance-based restricted stock units granted.

Is Chintu Patel’s Amneal (AMRX) RSU grant an open-market stock purchase or sale?

No, this transaction is a grant of performance-based restricted stock units as compensation, not an open-market purchase or sale. The units were awarded at a stated price of $0.00 per unit and convert into shares only if performance and vesting conditions are satisfied.

How does the RSU grant affect Chintu Patel’s Amneal (AMRX) derivative holdings?

After the grant, Chintu Patel holds 544,663 performance-based restricted stock units related to Amneal Class A common stock. These units represent a potential future equity position, contingent on meeting stock price performance targets and vesting conditions through the end of the February 28, 2029 performance period.